|
New study results on Dulcolax® confirm efficacy and safety
|
13 May 2010 |
|
Boehringer Ingelheim and Micromet announce global collaboration for multiple myeloma BiTE antibody
|
06 May 2010 |
|
Boehringer Ingelheim grows faster than the pharmaceutical market
|
29 April 2010 |
|
Boehringer Ingelheim launches Global Venture Fund to foster innovation in life sciences
|
06 April 2010 |
|
Dabigatran etexilate shows greater reductions than warfarin
|
30 March 2010 |
|
Boehringer Ingelheim Animal Health closes deal to acquire Animal Health Business from Pfizer
|
28 October 2009 |
|
FDA approves Micardis® (telmisartan) as the first treatment in its class
|
20 October 2009 |
|
Access to HIV medication
|
08 October 2009 |
|
New data show patients with chronic low back pain maintained pain reduction on duloxetine
|
14 September 2009 |
|
Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 (Tovok)
|
10 August 2009 |
|
Good first six months in 2009 for Boehringer Ingelheim
|
30 July 2009 |
|
Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration
|
17 June 2009 |
|
Boehringer Ingelheim and DeveloGen AG announce agreement
|
15 May 2009 |
|
Outcome of new Mirapexin®/Sifrol® (pramipexole) study
|
04 May 2009 |
|
New diagnostic tool for Hypoactive Sexual Desire Disorder (HSDD) in women
|
04 March 2009 |
|
European CHMP adopts negative opinion on Cymbalta for the treatment of fibromyalgia
|
27 October 2008 |
|
ERS COPD Research Award 2008 sponsored by Boehringer Ingelheim
|
08 October 2008 |
|
Boehringer Ingelheim signs a license agreement with Evec Inc. for its fully-human antibody programme
|
03 October 2008 |
|
TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile
|
03 September 2008 |
|
Boehringer Ingelheim continued to post strong growth in local currencies in the first half of 2008
|
11 August 2008 |